Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Pharos IBio Co Ltd (388870)

KOSDAQ
Currency in KRW
Disclaimer
16,070.00
0.00(0.00%)
Real-time Data
388870 Scorecard
Fair Value
Day's Range
15,600.0016,360.00
52 wk Range
8,570.0025,000.00
Bid/Ask
16,050.00 / 16,080.00
Prev. Close
16,070
Open
16,170
Day's Range
15,600-16,360
52 wk Range
8,570-25,000
Volume
106,389
Average Vol. (3m)
858,472
1-Year Change
-
Shares Outstanding
12,918,962
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

49,500
083450
+0.10%
110,300
000250
-5.73%
72,300
000100
0.00%
17,120
034020
+0.23%
How do you feel today about 388870?
Vote to see community's results!
or

Pharos IBio Co Ltd Company Profile

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-protein inhibitor for the treatment of metastatic cancer; PHI-401, an anaplastic lymphoma kinase (ALK) protein inhibitor; and PHI-501 a pan-RAF/DDRs inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.